Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Nov;48(6):101370.
doi: 10.1016/j.diabet.2022.101370. Epub 2022 Jun 29.

Smoking and diabetes interplay: A comprehensive review and joint statement

Vincent Durlach  1 , Bruno Vergès  2 , Abdallah Al-Salameh  3 , Thibault Bahougne  4 , Farid Benzerouk  5 , Ivan Berlin  6 , Carole Clair  7 , Jacques Mansourati  8 , Alexia Rouland  9 , Daniel Thomas  10 , Philippe Thuillier  11 , Blandine Tramunt  12 , Anne-Laurence Le Faou  13
Affiliations
Review

Smoking and diabetes interplay: A comprehensive review and joint statement

Vincent Durlach et al. Diabetes Metab. 2022 Nov.

Abstract

Evidence shows that smoking increases the risk of pre-diabetes and diabetes in the general population. Among persons with diabetes, smoking has been found to increase the risk of all-cause mortality and aggravate chronic diabetic complications and glycemic control. The current paper, which is a joint position statement by the French-Speaking Society on Tobacco (Société Francophone de Tabacologie) and the French-Speaking Society of Diabetes (Société Francophone du Diabète), summarizes the data available on the association between smoking and diabetes and on the impact of smoking and smoking cessation among individuals with type 1, type 2, and gestational diabetes mellitus. It also provides evidence-based information about the pharmacological and behavioral strategies for smoking cessation in these patients.

Keywords: Complications; Diabetes; Pre-diabetes; Smoking; Smoking cessation.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest Vincent Durlach has acted as an advisory board member, speaker, and/or consultant for Amgen, Sanofi, Lilly, Servier, and Bioprojet. Bruno Vergès reports grants, honoraria and institutional funding from Amgen, AstraZeneca, Bayer Pharma, Boehringer-Ingelheim, LifeScan, Lilly, MSD, Novo Nordisk, and Recordati. Abdallah Al-Salameh reports personal fees from Novo Nordisk, AstraZeneca, and Lilly. Daniel Thomas has received honoraria from Pfizer for punctual consulting, lectures and presentations, and support for attending meetings/travel. Philippe Thuillier reports personal fees from Novo Nordisk and Sanofi. Blandine Tramunt reports personal fees from Novo Nordisk and Lilly. Anne-Laurence Le Faou has received personal fees from Pfizer and Johnson and Johnson. The other authors declare that they have no conflicting interests.

LinkOut - more resources